Nicholson Wealth Management Group LLC Acquires 640 Shares of Zoetis Inc. $ZTS

Nicholson Wealth Management Group LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 7.7% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,933 shares of the company’s stock after purchasing an additional 640 shares during the period. Nicholson Wealth Management Group LLC’s holdings in Zoetis were worth $1,393,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Brighton Jones LLC raised its stake in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the period. Premier Path Wealth Partners LLC raised its stake in Zoetis by 3.0% during the 1st quarter. Premier Path Wealth Partners LLC now owns 5,549 shares of the company’s stock worth $914,000 after acquiring an additional 161 shares during the period. Boston Trust Walden Corp raised its stake in Zoetis by 18.2% during the 1st quarter. Boston Trust Walden Corp now owns 49,018 shares of the company’s stock worth $8,071,000 after acquiring an additional 7,542 shares during the period. Blue Trust Inc. raised its stake in Zoetis by 23.4% during the 1st quarter. Blue Trust Inc. now owns 5,238 shares of the company’s stock worth $862,000 after acquiring an additional 992 shares during the period. Finally, Roberts Wealth Advisors LLC raised its stake in Zoetis by 0.9% during the 1st quarter. Roberts Wealth Advisors LLC now owns 19,162 shares of the company’s stock worth $3,155,000 after acquiring an additional 170 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.6%

Zoetis stock opened at $144.15 on Friday. The stock has a market cap of $63.88 billion, a P/E ratio of 24.81, a PEG ratio of 2.30 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $193.49. The firm’s 50 day moving average price is $148.73 and its 200-day moving average price is $153.76.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the firm posted $1.56 earnings per share. Zoetis’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Ratings Changes

A number of research firms have commented on ZTS. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.